Oral pre-exposure prophylaxis initiation, continuation and adherence among pregnant and postpartum women receiving antenatal and postnatal care: a systematic review.

ABSTRACT:

Introduction

In 2023, one-fourth of new HIV acquisitions in children globally resulted from vertical transmission following incident HIV during pregnancy or breastfeeding. Oral pre-exposure prophylaxis (PrEP) with tenofovir disoproxil and emtricitabine is safe and effective in pregnancy and postpartum, with long-acting options emerging. Integrating PrEP into antenatal and postnatal care (ANC/PNC) is a crucial person-centred approach to prevent maternal HIV acquisition and vertical transmission. This review summarizes oral PrEP initiation, continuation and adherence among pregnant and postpartum women receiving ANC/PNC.

Methods

We systematically searched three databases for English-language quantitative studies published between 1 January 2015 and 28 March 2024. Eligible stud

SUBMITTER: Rotsaert A 

PROVIDER: S-EPMC12505019 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature